12/15-Lipoxygenase Inhibitor, ML351

Cell permeable: yes

Primary Target
12/15-LOX

Reversible: yes

Toxicity: Standard Handling (A)

A cell-permeable, non-toxic naphthyl-oxazole compound that acts as a highly potent, selective, active site directed, mixed type inhibitor of lipoxygenase-12/15 (IC₅₀ = 200 nM for human). The inhibition appears to be non-reductive and reversible in nature. Displays excellent selectivity over 5-LOX (IC₅₀ >50 µM), 12-LOX (IC₅₀ >100 µM), and 15-LOX (IC₅₀ >100 µM) and does not affect the activity of COX-1 and -2 in any significant manner (<10% inhibition at 15 µM). Can cross the blood brain barrier (brain to plasma ratio = 2.8). Offers protection against glutamate-induced oxidative toxicity in mouse neuronal HT22 cells and reduces the size of infarcts in a murine model of ischemic stroke. Displays good aqueous stability over a wide range of pH. Exhibits attractive pharmacokinetic properties (t_1/2 ~ 1 h in both plasma and brain; C_max of 13.8 and 28.8 µM in plasma and brain, respectively; at 30 mg/kg, i.p).

Please note that the molecular weight for this compound is batch-specific due to variable water content.

Rai, G., et al. 2014. J. Med. Chem.57, 4035.

Packaged under inert gas

Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany